Potential Role of Donor-Derived Cell Free DNA as a New Biomarker in Cardiac Allograft Vasculopathy (FreeDNA-CAV)
There is an unmet need for a noninvasive biomarker for cardiac allograft vasculopathy (CAV), that could obviate the need to perform surveillance coronary angiograms in HT recipients. Donor-derived cell free DNA (ddcf-DNA) has shown a good ability to rule out cellular rejection, but its performance as a biomarker for CAV has not been tested.We sought to evaluate the performance of ddcf-DNA as a biomarker of CAV in a cohort of patients undergoing routine coronariography.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: M. Jimenez-Blanco Bravo, L. Perez Gomez, C. Arellano Serrano, M. Torres Sanabria, F. Hernandez Perez, J. Oteo Dominguez, S. Mingo Santos, C. Mitroi, V. Mo ñivas Palomero, M. Gomez Bueno, J. Segovia Cubero Tags: (560) Source Type: research
More News: Angiography | Bone Graft | Cardiology | Heart | Heart Transplant | Lung Transplant | Transplant Surgery | Transplants